Literature DB >> 33710391

Incidence of vasovagal syncope in Mohs surgery.

Julian Stashower1, Jamison E Strahan2.   

Abstract

Although vasovagal syncopal episodes (VSE) are a well-known complication of dermatologic surgery, there are currently no studies that report an incidence of VSE in Mohs surgery specifically. This study aims to provide data on the incidence of VSE in Mohs surgery by reviewing VSE incident reports from a private, community-based, outpatient Mohs surgery clinic. We report an incidence of VSE of 0.09% in Mohs surgery. This study offers the first data on the incidence of VSE during Mohs surgery and suggests that the incidence of VSE in Mohs surgery may be lower than what has been quoted as the reference standard for dermatologic surgery.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dermatologic surgery; Incidence of vasovagal syncope; Mohs; Mohs surgery; Vasovagal syncope

Mesh:

Year:  2021        PMID: 33710391     DOI: 10.1007/s00403-021-02215-0

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.033


  4 in total

1.  Complications of minor skin surgery performed under local anesthesia.

Authors:  Avshalom Shalom; Melvyn Westreich; Eran Hadad; Tal Friedman
Journal:  Dermatol Surg       Date:  2008-05-06       Impact factor: 3.398

Review 2.  Medical issues and emergencies in the dermatology office.

Authors:  D J Fader; T M Johnson
Journal:  J Am Acad Dermatol       Date:  1997-01       Impact factor: 11.527

3.  A prospective study of the incidence of complications associated with dermatological surgery.

Authors:  J M Amici; A M Rogues; A Lasheras; J P Gachie; P Guillot; C Beylot; L Thomas; A Taïeb
Journal:  Br J Dermatol       Date:  2005-11       Impact factor: 9.302

4.  Adverse events with outpatient anesthesia in Massachusetts.

Authors:  Edward M D'eramo; Steven J Bookless; Joanne B Howard
Journal:  J Oral Maxillofac Surg       Date:  2003-07       Impact factor: 1.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.